22Z.F · Zealand Pharma A/S

-

Please sign in to comment on 22Z.F

1 Comment

Admin

4 years, 1 month ago

Zealand Pharma A/S is currently in a long term downtrend where the price is trading 7.8% below its 200 day moving average.

From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 21.0.

Zealand Pharma A/S's total revenue rose by 451.3% to $63M since the same quarter in the previous year.

Its net income has dropped by 96.5% to $-381M since the same quarter in the previous year.

Finally, its free cash flow fell by 56.4% to $-277M since the same quarter in the previous year.

Based on the above factors, Zealand Pharma A/S gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	F
CurrencyCode	EUR
ISIN	DK0060257814

Market Cap	5B
PE Ratio	None
Target Price	222.65
Beta	0.58
Dividend Yield	None

ABOUT

Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.

22Z.F · Zealand Pharma A/S

-

Zealand Pharma A/S

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Zealand Pharma A/S using a moving average strategy